News

HDA Media And Political Bulletin – 13 May 2016

Dispensing errors and automated dispensing research

12 May 2016, PSNC

 

PSNC has published a paper examining the research around dispensing errors and automated dispensing in pharmacy. The paper found that the research used to inform the government proposals was conducted prior to the introduction of the Electronic Prescription Service (EPS). As the majority of the labelling errors identified in the research will now be prevented by the EPS, PSNC concludes that automated dispensing systems are unlikely to further reduce the error rates.

 

Questions raised over DH hub and spoke proposals

12 May 2016, P3 Pharmacy

 

P3 Pharmacy also reports on the validity of the data used to inform the government’s proposals for hub-and-spoke dispensing. NPA public affairs manager, Gareth Jones, stated that the data presented by the Department of Health was misleading and flawed, and stressed there must be a fair representation of error rates.

 

EU exit will jeopardise drug research and development, warns ABPI

12 May 2016, Pharmacy Biz, Neil Trainis

 

The ABPI has warned that drug research and development in the UK may be compromised if the country leaves the UK due to a lack of EU funding and a breakdown in international collaboration. The ABPI has also warned that licensing difficulties will jeopardise rapid access to new medicines.

 

ABPI welcomes Office for Life Sciences publication of Early Access to medicines Scheme report

12 May 2016, ABPI

 

The ABPI has welcomed the publication of ‘Early access to medicines scheme: (EAMS) how the scheme works’. The publication provides further detail about how EAMS fits into healthcare, and will assist stakeholders in navigating through the EAMS process.

 

Parliamentary Coverage

House of Commons, Written Answers, Drugs: Wholesale Trade, 12 May 2016

 

Asked by Charlotte Leslie (MP): If he will take steps to increase competition in the pharmaceutical wholesale market.

 

Department of Health

 

Answered by George Freeman (MP): The United Kingdom has an active and diverse licensed wholesale dealing market for medicinal products for human use which is regulated by the Medicines and Healthcare products Regulatory Agency. It is up to individual companies to submit such licence applications.

If there is concern with anti-competiveness, this should be referred to the Competition and Markets Authority.

 

Full Coverage

Dispensing errors and automated dispensing research

12 May 2016, PSNC

 

PSNC has today published a paper examining the research around dispensing errors and automated dispensing in pharmacy.

 

The paper highlights statistics produced from the research and comments on their validity in assessing the impact of automation on reducing dispensing errors.

 

Dispensing errors and automated dispensing in community pharmacy

 

PSNC wrote this paper in response to comments made by the Chief Pharmaceutical Officer, Dr Keith Ridge, during an evidence session of the All-Party Pharmacy Group (APPG) held on 16th March 2016. The APPG reported that Dr Ridge noted dispensing errors in community pharmacy occur in around 3% of all items dispensed, whilst large-scale automated dispensing would reduce the error rate to 0.00001%.

 

PSNC welcomes a recent clarification of these comments from Dr Ridge in which further detail is given about where he acquired his figures and he acknowledges that it was not appropriate to draw a direct comparison between the two.

 

 

Questions raised over DH hub and spoke proposals

12 May 2016, P3 Pharmacy

 

Questions have been raised over data on dispensing errors used by the Department of Health as the basis for an argument for the wider use of hub and spoke dispensing.

 

England’s chief pharmaceutical officer Dr Keith Ridge has offered a “clarification on comments he made during the meeting on dispensing error rates in community pharmacy vs. automated systems”, says the All Party Pharmacy Group, referring to a statement from Dr Ridge posted on their website.

 

In the response to questions raised at a recent APPG meeting, Dr Ridge says in the clarification that revisiting evidence presented for dispensing error rates in pharmacy, including a study from Sweden where hub and spoke is used, has made him ask “further questions”. “Now that I know the error rate from Sweden is determined by reporting, it is not appropriate draw a direct comparison… I apologise for inadvertently misleading the committee and for any subsequent confusion,” he said. “However, I do remain of the view that automated centralised dispensing, underpinned by a robust quality assurance and regulatory system, resilient and implemented carefully, will improve safety and quality of patient care.”

 

The DH proposals are “unravelling” says the National Pharmacy Association. Commenting on the development, Gareth Jones, public affairs manager at the NPA, said that the original data presented was misleading and “flawed”, with further investigation now urgently needed. “We understand that the chief pharmaceutical officer has accepted that he misled the All-Party Pharmacy Group in relation to safety data for hub and spoke models. The Department of Health’s hub and spoke proposal is flawed – and this is just one of many claims that are unravelling. But he still needs to go further in order to ensure that the APPG and anyone planning to respond to the consultation has a fair representation of the error rate literature.”

 

A consultation on the potential for the wider adoption of the hub and spoke model is due to close on 17 May.

 

 

EU exit will jeopardise drug research and development, warns ABPI

12 May 2016, Pharmacy Biz, Neil Trainis

 

The Association of the British Pharmaceutical Industry has warned that drug research and development in the UK and rapid access to new medicines will be jeopardised if the country votes to leave the European Union.

 

There is growing momentum behind a stay-in-the-EU campaign within pharmacy, marked recently by an article distributed by Sigma Pharmaceuticals and written by Pharmacy Voice chair Claire Ward and Sigma director Bhavin Shah warning of the dangers posed to community pharmacy and patient health if the UK votes to leave on June 23.

 

Mike Thompson, the chief executive of the ABPI, waded into the debate, arguing that an exit would result in the UK losing EU funding which in turn could hamper the development of critical medicines.

 

“Our members are overwhelmingly supportive of remaining in the EU. We believe that staying in the EU will mean that patients in the UK will be more likely to get faster access to new medicines than if we left,” he said.

 

“With the European Medicines Agency, pharmaceutical companies have a one-stop shop for centralised licensing of new medicines and treatments across Europe. If we left the EU this would mean that the licensing of new medicines would have to be handled by a UK agency as well as a European agency.

 

“Our members have confirmed that the applications for UK licence would come after the European licence due to the smaller patient population in the UK.

 

“The UK also currently holds an enviable position as one of the premier European destinations for ground-breaking research and clinical trials. An EU exit risks the breakdown of international collaboration between scientists, doctors and industry which could slow down access to new drugs for patients in the UK.

 

“As a nation we benefit hugely from EU funding for research and development, more than any other EU country, and this has helped drive medicines research across a whole range of diseases, including cancer, dementia and diabetes.

 

“An EU exit would create a funding gap which would need to be filled if the UK is to continue punching above its weight globally in research and development of new treatments.”

 

Thompson added: “We believe that staying in the EU will also encourage global pharmaceutical companies to continue to invest, employ, research, manufacture and export in the UK, rather than elsewhere.”

 

 

ABPI welcomes Office for Life Sciences publication of Early Access to medicines Scheme report

12 May 2016, ABPI

 

The Association of the British Pharmaceutical Industry (ABPI) welcomes the publication of ‘Early access to medicines scheme : how the scheme works’ on the Office for Life Sciences webpages.

 

​​The Association of the British Pharmaceutical Industry (ABPI) welcomes the publication of ‘Early access to medicines scheme : how the scheme works’ on the Office for Life Sciences webpages.

 

Commenting on the release of the Dr Paul Catchpole, Value & Access Director, said, “ABPI welcomes the publication by the Office for Life Sciences of operational guidance and principles to support the Early Access to Medicines Scheme (EAMS).   Providing further detail and signposting about how EAMS fits across the entire patient access pathway spanning the Medicines and Healthcare Products Regulatory Agency (MHRA), the National Institute for Health and Care Excellence( NICE) and NHS England will help stakeholders navigate through the EAMS process and helps further clarify the benefits of participating in EAMS.

 

“We look forward to further dialogue around EAMS when the Accelerated Access Review is published, including the review team’s consideration of the PwC independent EAMS review already published as part of this work”

HDA Media And Political Bulletin – 13 May 2016

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?